Your browser is no longer supported. Please, upgrade your browser.
Settings
JNJ Johnson & Johnson daily Stock Chart
JNJ [NYSE]
Johnson & Johnson
IndexDJIA S&P500 P/E20.61 EPS (ttm)5.49 Insider Own0.02% Shs Outstand2.76B Perf Week0.37%
Market Cap311.73B Forward P/E16.16 EPS next Y7.00 Insider Trans-21.98% Shs Float2.75B Perf Month1.23%
Income15.38B PEG3.44 EPS next Q1.69 Inst Own67.00% Short Float0.82% Perf Quarter8.23%
Sales70.18B P/S4.44 EPS this Y-3.90% Inst Trans-0.64% Short Ratio3.05 Perf Half Y12.49%
Book/sh26.35 P/B4.29 EPS next Y5.90% ROA11.50% Target Price117.44 Perf Year16.26%
Cash/sh14.45 P/C7.82 EPS next 5Y6.00% ROE21.50% 52W Range80.04 - 114.18 Perf YTD11.66%
Dividend3.20 P/FCF49.36 EPS past 5Y2.80% ROI16.90% 52W High-0.99% Beta0.59
Dividend %2.83% Quick Ratio2.50 Sales past 5Y2.60% Gross Margin69.30% 52W Low41.26% ATR0.99
Employees127100 Current Ratio2.80 Sales Q/Q0.60% Oper. Margin27.00% RSI (14)57.92 Volatility0.67% 0.82%
OptionableYes Debt/Eq0.32 EPS Q/Q0.40% Profit Margin21.90% Rel Volume0.63 Prev Close112.90
ShortableYes LT Debt/Eq0.28 EarningsApr 19 BMO Payout53.90% Avg Volume7.37M Price113.06
Recom2.40 SMA200.39% SMA502.26% SMA20011.66% Volume4,457,300 Change0.14%
May-20-16Initiated Standpoint Research Sell $94
Apr-20-16Reiterated RBC Capital Mkts Outperform $122 → $125
Apr-20-16Reiterated Piper Jaffray Neutral $105 → $106
Apr-15-16Reiterated RBC Capital Mkts Outperform $114 → $122
Mar-14-16Upgrade Goldman Sell → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $101 → $115
Oct-05-15Resumed Piper Jaffray Neutral $105
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Dec-16-13Reiterated Deutsche Bank Hold $93 → $95
Jul-18-13Reiterated Argus Buy $96 → $104
Jul-17-13Reiterated Barclays Overweight $95 → $99
Jul-17-13Downgrade Deutsche Bank Buy → Hold $92 → $93
Apr-18-13Reiterated Argus Buy $80 → $96
Apr-15-13Reiterated Barclays Overweight $85 → $95
May-30-16 11:07AM  Why Eliquis Matters to Bristol-Myers Squibbs Cardiovascular Business
09:07AM  Johnson & Johnson Initiated With Sell Rating (JNJ) at Investopedia
May-28-16 02:18PM  Bet You Can't Guess Which of These 10 Big Pharma Names Has the Largest Late-Stage Pipeline at Motley Fool
09:40AM  Portola Pharmaceuticals: Does New Data Get It Back on Track? at Motley Fool
May-27-16 02:59PM  Billionaires Are Gobbling Up Johnson & Johnson's Stock -- Should You? at Motley Fool
01:10PM  5 Dividend-Paying Stocks to Give New Grads at Kiplinger
12:47PM  G7 May Have Just Given Green Light To Buy Stocks at Forbes
11:54AM  Remember these? Pinto, Tylenol and other infamous recalls
11:42AM  3 Stand-Out Health Care Stocks for Dividends and Growth
10:04AM  The sky isnt falling on the economy
09:43AM  2016 Global 2000: The World's Largest Drug And Biotech Companies at Forbes
09:30AM  Zacks Investment Ideas feature highlights: Canadian Pacific Railway, Facebook and Johnson & Johnson
09:15AM  Morning Technical Breakdown Highlights on Big Drug Makers Stocks
05:43AM  2016 Global 2000: The World's Largest Drug And Biotech Companies
May-26-16 07:47PM  U.S. sees first case of bacteria resistant to all antibiotics Reuters
04:53PM  How to Buy Momentum, Trade Options and Short Stocks
03:24PM  Hedge Funds Are Buying These Stocks, Should You?
03:10PM  Will Medtronic Beat Analysts Revenue Estimates in 4Q16?
11:02AM  Is Bristol-Myers Squibbs Valuation High?
10:29AM  Jim Cramer -- Despite Rally, HP Earnings Not Impressive
09:04AM  Better Buy: Gilead Sciences Inc. vs. Johnson & Johnson at Motley Fool
May-25-16 03:50PM  Novo Nordisk IDegLira Recommended by FDA Advisory Committee
10:33AM  Johnson & Johnson to Participate in the Goldman Sachs 37th Annual Global Healthcare Conference PR Newswire
09:47AM  Celgene, JNJ, Takeda to Drive Myeloma Drug Sales
04:39AM  AGs: Pelvic mesh implants caused dire complications
May-24-16 04:39PM  California sues Johnson & Johnson over marketing for pelvic mesh Reuters
03:07PM  California AG sues Johnson & Johnson over marketing for pelvic mesh Reuters
02:13PM  Trump says decision to seek donations followed GOP request
12:05PM  Tuesday links: consistent declines
10:25AM  The Top 5 Johnson & Johnson Shareholders (JNJ) at Investopedia
09:58AM  4 Dow Members Bucking the Negative Trend
08:06AM  3 Stocks With Better Dividends Than Johnson & Johnson at Motley Fool
May-23-16 06:04PM  Ignore Intuitive Surgical, Inc.: Here Are 3 Better Stocks at Motley Fool
04:00PM  Samsung Bioepis applies for approval to sell Remicade biosimilar in U.S. Reuters
03:27PM  What Hedge Funds Think About Achillion Pharmaceuticals, Inc. (ACHN)? at Insider Monkey
12:55PM  France faults Bial and Biotrial over fatal drug trial Reuters
09:50AM  Warren Buffetts Favorite Consumer Products Stocks at 24/7 Wall St.
09:03AM  [$$] Triple-A quality fades as companies embrace debt at Financial Times
May-22-16 11:15PM  American Beacon: Top 3 Single Equity Manager Mutual Funds (BRLVX, SGAGX) at Investopedia
May-21-16 10:45AM  6 Large Cap Stocks Analysts Want You to Sell Now at 24/7 Wall St.
May-20-16 05:30PM  Stocks for rainy day trades
04:31PM  Wal-Mart PT Hiked; J&J Started At Sell; ICE Is A Buy
01:23PM  One Reason Why Johnson & Johnson (JNJ) Stock Is Retreating Today
12:36PM  J&J is Worth as Much as Gilead, Biogen, Mylan, Celgene and Teva Combined. It's Time to Sell. at Barrons.com
12:10PM  Johnson & Johnson Stock Trades Ex-Dividend Friday (JNJ) at Investopedia
09:03AM  In Your 60s? 3 Stocks You Should Consider Buying at Motley Fool
08:18AM  JOHNSON & JOHNSON Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:36AM  Coverage initiated on Johnson & Johnson by Standpoint Research
May-19-16 03:54PM  J&J's Consumer, Medical Device Businesses Will Drive Growth
03:24PM  Will Johnson & Johnson (JNJ) Stock Rise as Wells Fargo Sees Solid Growth?
01:04PM  [$$] Johnson & Johnson Stock Could Reach $127 at Barrons.com
May-18-16 05:32PM  Why Charter Communications, MacroGenics, and TD Ameritrade Jumped Today at Motley Fool
05:28PM  Pfizer says will present data on 6 drugs at ASCO meeting
03:40PM  J&J CEO: Disappointed in talcum verdict findings
01:14PM  4 Healthy Dividend Stocks For Your Portfolio at TheStreet
09:01AM  J&J CEO: Consumer brands, medical devices poised for growth at CNBC
09:01AM  J&J CEO: Consumer brands, medical devices poised for growth at CNBC
07:18AM  JNJ CEO: Renewed focus on innovation
07:15AM  JNJ CEO: Restructuring growth
06:45AM  Johnson & Johnson Showcasing its Broad Innovation and Technology Strategies in Consumer and Medical Device Businesses PR Newswire
06:45AM  JNJ's next $1 billion brands
May-17-16 04:41PM  J&J to stand behind talc's safety at upcoming trials -lawyer Reuters
02:18PM  3 Perfect Stocks for Retirees in Their 60s to Consider Buying at Motley Fool
01:54PM  J&Js Baby Needs a Makeover as Moms Go Natural With Jessica Alba at Bloomberg
10:18AM  Johnson & Johnson Aligns With HP To Create Personalized Healthcare Solutions Benzinga
08:46AM  Johnson & Johnson Announces Collaboration with HP Inc. Subsidiary to Create Personalized Health Care Solutions with 3D Printing Technologies PR Newswire
May-16-16 07:01PM  Cramer: Dow Components, Part 2 -- A Whole Lot of Nothing at TheStreet
03:53PM  An ETF That Takes Investors To Dividend Growth Benzinga
02:08PM  Jim Cramer -- Quick Take on 30 Stocks and What Investors Are Missing at TheStreet
12:34PM  Warren Buffett Owns Johnson & Johnson -- Should You? at TheStreet
09:07AM  How Colgate Increased Operating Income in Africa/Eurasia Region Market Realist
08:07AM  Why Is Remicade Driving Down Mercks Performance? Market Realist
04:42AM  Reverse Yankees refuse to go home Reuters
May-15-16 09:49AM  Smart Investors Are Already Buying These Stocks for Retirement at Motley Fool
07:00AM  An Attractive Vanguard Dividend Fund Turns 10 Morningstar
May-14-16 01:04PM  JOHNSON & JOHNSON Financials EDGAR Online Financials
May-13-16 04:00PM  Johnson & Johnson slips after analyst digs at device prospects at CNBC
03:09PM  Johnson & Johnson (JNJ) Stock Slumps on Ratings Downgrade at TheStreet
01:35PM  Boyd Watterson Resolutes on Top Stock Picks for This Quarter at Insider Monkey
11:04AM  Trending Stocks: Facebook, Activision Blizzard, Johnson & Johnson and More at Insider Monkey
08:15AM  Early movers: JCP, JWN, DDS, TIF, SHAK, JNJ, AGN, HMC & more at CNBC
07:13AM  Today's Top 5 Stock Picks: Blue Chip Dividend Payers at Barrons.com
May-12-16 12:20PM  Stocks: Healthcare's More Than Just Biotech at Barrons.com
09:35AM  Analyzing Medivations Growth Opportunity with Xtandi Market Realist
09:17AM  Bill Doyle's Pershing Exit Adds to Disastrous Quarter for Bill Ackman at TheStreet
08:59AM  How to Trade Johnson & Johnson Stock at All-Time Highs at TheStreet
May-11-16 04:37PM  Retailers lead a broad decline in stocks as Macy's plunges AP
04:31PM  Why Endo International plc Investigated a Lower Price at Motley Fool
03:47PM  Mercks Valuation Cheat Sheet for Fiscal 1Q16 Market Realist
02:45PM  Epirus exec sees promise for biosimilars despite setback for company at American City Business Journals
12:58PM  DOJ Investigation Has Little Impact on Pharmas' Share Prices at TheStreet
08:30AM  Actress Kristen Bell Pays a Surprise Visit to Nurses at Providence Saint Joseph Medical Center in Los Angeles in Celebration of Nurses Week Business Wire
08:08AM  Reverse Yankees storm heavily supplied European bond market Reuters
08:05AM  25 Companies Raising Their Dividends for 25 Years or More at 24/7 Wall St.
07:00AM  Insulet Shares Swoon on Insurer Decision, but Fair Value Is Unchanged Morningstar
12:14AM  [$$] U.S. Investigates Drugmaker Contracts With Pharmacy-Benefit Managers at The Wall Street Journal
May-10-16 09:35PM  U.S. probes contracts between drugmakers, pharmacy benefit managers Reuters
06:31PM  Cramer: Why this is a huge week for big money on Wall Street at CNBC
06:21PM  Feds investigate drugmakers ties to pharmacy-benefit managers at MarketWatch
05:14PM  US probes contracts between drugmakers, pharmacy benefit managers Reuters
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women's health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages under the BAND-AID brand name and first aid products under the NEOSPORIN brand name. This segment also provides over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company offers its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kapusta Ronald AController, CAOMay 10Option Exercise58.333,957230,81229,682May 12 05:09 PM
Kapusta Ronald AController, CAOMay 10Sale114.773,957454,15725,725May 12 05:09 PM
Caruso Dominic JVP, Finance; CFOFeb 08Option Exercise0.0029,0050125,466Feb 10 06:02 PM
Gorsky AlexChairman, CEOFeb 08Option Exercise0.0067,9330197,441Feb 10 06:02 PM
PETERSON SANDRA EGroup Worldwide ChairmanFeb 08Option Exercise0.007,633037,943Feb 10 06:03 PM
Fasolo PeterVP, Global Human ResourcesFeb 08Option Exercise0.0018,777056,512Feb 10 06:03 PM
Ullmann Michael HVP, General CounselFeb 08Option Exercise0.0016,697098,071Feb 10 06:03 PM
Stoffels PaulusChief Scientific OfficerFeb 08Option Exercise0.0028,2420131,104Feb 10 06:03 PM
Kapusta Ronald AController, CAOFeb 08Option Exercise0.002,598026,023Feb 10 06:03 PM
Fasolo PeterVP, Global Human ResourcesFeb 03Option Exercise72.54144,56810,486,963182,303Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 03Sale104.12144,56815,052,42037,735Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 02Option Exercise72.546,817494,50544,552Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 02Sale104.096,817709,58837,735Feb 04 06:04 PM
Caruso Dominic JVP, Finance; CFOJan 15Option Exercise0.0011,6020100,336Jan 20 07:25 PM
Fasolo PeterVP, Global Human ResourcesJan 15Option Exercise0.007,511040,578Jan 20 07:25 PM
Gorsky AlexChairman, CEOJan 15Option Exercise0.0027,1730140,534Jan 20 07:25 PM
PETERSON SANDRA EGroup Worldwide ChairmanJan 15Option Exercise0.003,053031,616Jan 20 07:25 PM
Ullmann Michael HVP, General CounselJan 15Option Exercise0.006,679083,907Jan 20 07:25 PM
Kapusta Ronald AController, CAOJan 15Option Exercise0.003,896024,699Jan 20 07:25 PM
Stoffels PaulusChief Scientific OfficerJan 15Option Exercise0.0011,2970106,585Jan 20 07:25 PM
PETERSON SANDRA EGroup Worldwide ChairmanDec 17Option Exercise0.0021,688040,730Dec 21 05:09 PM
Ullmann Michael HVP, General CounselNov 20Option Exercise58.3422,6261,320,00194,878Nov 24 01:00 PM
Ullmann Michael HVP, General CounselNov 20Sale102.4717,6501,808,54377,228Nov 24 01:00 PM
Caruso Dominic JVP, Finance; CFONov 02Option Exercise58.3420,5691,199,995109,303Nov 04 05:05 PM
Caruso Dominic JVP, Finance; CFONov 02Sale102.2120,5692,102,42388,734Nov 04 05:05 PM
Kapusta Ronald AController, CAOOct 23Option Exercise58.346,239363,98327,042Oct 27 03:38 PM
Kapusta Ronald AController, CAOOct 23Sale99.686,239621,90420,803Oct 27 03:38 PM
PRINCE CHARLESDirectorAug 06Buy99.252,500248,13225,645Aug 10 12:49 PM
PRINCE CHARLESDirectorJun 02Buy99.222,500248,05023,145Jun 03 05:20 PM